Business, energy, technology, markets and global industry news from Business News Today

Epcore DLBCL-1

PharmaDeviceNews Epcore DLBCL-1
A clinician reviews lymphoma treatment data as Genmab and AbbVie clarify that the Phase 3 EPCORE DLBCL-1 trial missed its sole United States overall survival endpoint despite a progression-free survival benefit for epcoritamab. Representative image.
Pharma & Biotech

Genmab and AbbVie clarify EPCORE DLBCL-1 missed sole US overall survival endpoint

Genmab and AbbVie clarify that EPCORE DLBCL-1 missed its sole US overall survival endpoint despite a PFS benefit for epcoritamab.

Read More
Pharma & Biotech

How AbbVie’s epcoritamab reshapes the competitive calculus in relapsed diffuse large B-cell lymphoma

AbbVie’s Phase 3 epcoritamab data raise critical questions about survival endpoints and bispecific antibodies in relapsed lymphoma. Read the full analysis.

Read More
Pharma & Biotech

Can epcoritamab reshape salvage DLBCL care? Genmab’s Phase 3 data brings regulatory momentum

Genmab’s epcoritamab improved PFS in a Phase 3 DLBCL trial. Find out how this could reshape bispecific monotherapy in aggressive B-cell lymphoma care.

Read More